Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $0.00 | $20.1M | $0.00 | $151K | $3.55M | $244M |
| Revenue growth | — | -100.0% | — | -100.0% | — | 2251.0% | 6775.0% |
| Operating income | -$10.6M | -$46.7M | -$56.4M | -$115M | -$170M | -$211M | $67.6M |
| Operating margin | -105.6% | — | -280.5% | — | -112543.7% | -5939.0% | 27.7% |
| Net income | -$12.3M | -$45.4M | -$58.7M | -$105M | -$153M | -$187M | $87.0M |
| Net margin | -123.4% | — | -292.3% | — | -101319.2% | -5277.5% | 35.7% |
| EPS (diluted) | -$6.08 | -$2.93 | -$2.52 | -$4.15 | -$5.20 | -$5.00 | $2.30 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.0M | -$36.9M | -$62.1M | -$70.1M | -$125M | -$161M | $108M |
| Capital expenditures | $271K | $294K | $1.02M | $1.24M | $2.46M | $1.93M | $1.55M |
| Free cash flow | -$16.3M | -$37.2M | -$63.2M | -$71.3M | -$127M | -$163M | $106M |
| Share buybacks | — | — | — | — | — | $0.00 | $181M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.02M | $266M | $230M | $279M | $331M | $560M | $287M |
| Total assets | $11.0M | $269M | $255M | $307M | $370M | $616M | $338M |
| Total liabilities | $10.5M | $7.72M | $12.1M | $29.4M | $37.8M | $44.3M | $34.9M |
| Shareholders' equity | -$19.4M | $262M | $243M | $277M | $332M | $572M | $303M |
| Retained earnings | -$19.6M | -$65.0M | -$124M | -$228M | -$381M | -$569M | -$482M |
| Shares (wtd avg diluted) | 2.43M | 15.5M | 23.3M | 25.2M | 29.4M | 37.4M | 37.9M |
Every figure is extracted from Keros Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.